Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 10, 2008, Pages 1851-1856

  Klein, Jonathan H ^a   Hegele, Robert A ^a,b   Hackam, Daniel G ^a,b   Koschinsky, Marlys L ^c   Huff, Murray W ^a,b   Spence, J David ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Atherosclerosis; Carotid; Lipoprotein(a); Plaque; Stenosis

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; LIPOPROTEIN A; BIOLOGICAL MARKER;

ADULT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBRINOLYSIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; THROMBOSIS; AGED; BLOOD; CARDIOVASCULAR DISEASE; ECHOGRAPHY; HOSPITALIZATION; INTERNAL CAROTID ARTERY; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT; RUPTURE; STATISTICAL MODEL;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; FEMALE; HUMANS; LINEAR MODELS; LIPOPROTEIN(A); LOGISTIC MODELS; MALE; MIDDLE AGED; PHENOTYPE; RISK ASSESSMENT; RISK FACTORS; RUPTURE; SEVERITY OF ILLNESS INDEX;

EID: 53449083122     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.169292     Document Type: Article

References (27)

1. Danesh J, Collins R, Peto R Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102:1082-1085.
2. Ohira T, Schreiner PJ, Morrisett JD, Chambless LE, Rosamond WD, Folsom AR. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2006;37:1407-1412.
3. Hegele RA. The genetic basis of atherosclerosis. Int J Clin Lab Res. 1997;27:2-13.
4. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.
5. Spence JD, Hegele RA. Noninvasive phenotypes of atherosclerosis: similar windows but different views. Stroke. 2004;35:649-653.
6. Spence JD, Hegele RA. Noninvasive phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:e188-e189.
7. Demer LL, Tintut Y. Mineral exploration: search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award lecture. Arterioscler Thromb Vasc Biol. 2003;23:1739-1743.
8. Koschinsky ML. Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein. Curr Atheroscler Rep. 2005;7:389-395.
9. Koschinsky ML. Lipoprotein(a) and the link between atherosclerosis and thrombosis. Can J Cardiol 2004;20 Suppl B:37B-43B.
10. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 2004;24:2219-2226.
11. Spence JD, Barnett PA, Bulman DE, Hegele RA. An approach to ascertain probands with a non traditional risk factor for carotid atherosclerosis. Atherosclerosis. 1999;144:429-434.
12. Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke. 2002;33:2916-2922.
13. Rothwell PM, Howard SC, Spence JD. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke. 2003;34:2583-2590.
14. Hegele RA, Freeman MR, Langer A, Connelly PW, Armstrong PW. Acute reduction of lipoprotein(a) by tissue-type plasminogen activator. Circulation. 1992;85:2034-2038.
15. Wolfe BM, Barrett PH, Laurier L, Huff MW. Effects of continuous conjugated estrogen and micronized progesterone therapy upon lipoprotein metabolism in postmenopausal women. J Lipid Res. 2000;41:368-375.
16. Wong WL, Eaton DL, Berloui A, Fendly B, Hass PE. A monoclonal-antibody- based enzyme-linked immunosorbent assay of lipoprotein(a). Clin Chem. 1990;36:192-1976.
17. Barnett PA, Spence JD, Manuck SB, Jennings JR. Psychological stress and the progression of carotid artery disease. J Hypertens. 1997;15:49-55.
18. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995;272:1421-1428.
19. Iemolo F, Martiniuk A, Steinman DA, Spence JD. Sex differences in carotid plaque and stenosis. Stroke. 2004;35:477-481.
20. Barnett HJM, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE, Spence JD. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe carotid stenosis. N Engl J Med. 1998;339:1415-1425.
21. Norris JW, Zhu CZ, Bornstein NM, Chambers BR. Vascular risks of asymptomatic carotid stenosis. Stroke. 1991;22:1485-1490.
22. Sanyal S, Karas RH, Kuvin JT. Present-day uses of niacin: effects on lipid and non-lipid parameters. Expert Opin Pharmacother. 2007;8:1711-1717.
23. Nagalski A, Bryla J. [Niacin in therapy]. Postepy Hig Med Dosw (Online). 2007;61:288-302.
24. Lai E, De L, I, Crumley TM, Liu F, Wenning LA, Michiels N, Vets E, O'Neill G, Wagner JA, Gottesdiener K. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype I. Clin Pharmacol Ther. 2007;81:849-857.
25. Cheng K, Wu TJ, Wu KK, Sturino C, Metters K, Gottesdiener K. Wright SD, Wang Z, O'Neill G, Lai E, Waters MG. Antagonism of the prostaglandin D2 receptor I suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103:6682-6687.
26. Meinertz H, Nilausen K, Hilden J. Alcohol-extracted, but not intact, dietary soy protein lowers lipoprotein(a) markedly. Arterioscler Thromb Vasc Biol. 2002;22:312-316.
27. Schulz UG, Rothwell PM. Sex differences in carotid bifurcation anatomy and the distribution of atherosclerotic plaque. Stroke. 2001;32: 1525-1531.